Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
hypersensitivity/turse
Link salvestatakse lõikelauale
Leht 1 alates 18 tulemused
Method for preventing or treating an allergic disease using extract from illicium verum
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to a method for preventing or treating an allergic disease using an extract from Illicium verum.
Description of the Related Art
Allergies are known as sensitive reaction which is caused by immune dysfunction innately or
Triazine derivatives to treat pain, fever, inflammation, allergies and thrombosis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
N-nicotinoylhalogenobenzoguanamines are known in the art to exhibit strong anti-inflammatory action (see Japanese patent application No. 56-87124). It has now been discovered that triazine derivatives of the formula (I): ##STR2## and pharmaceutically acceptable salts thereof wherein R.sup.1 and
1,3-diaryl cyclopentanes and derivatives thereof as PAF antagonists
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Platelet-activating factor (PAF) has recently been identified as an acetyl glyceryl ether phosphorylcholine (AGEPC), i.e., 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (Hanahan D. J. et al., J. Biol. Chem. 255:5514, 1980). Even before its chemical
1,3-diaryl cyclopentanes and derivatives thereof as PAF antagonists
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Platelet-activating factor (PAF) has recently been identified as an acetyl glyceryl ether phosphorylcholine (AGEPC), i.e., 1-0-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorycholine (Hanahan D. J., et al., J. Biol. Chem. 255:5514, 1980). Even before its chemical
Indolylmaleimide derivatives
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
Indolylmaleimide derivatives
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein
R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl,
R.sub.b
Indolylmaleimide derivatives
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
Therapeutic treatment for skin disorders
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is broadly directed to a method of inhibiting or decreasing vascular permeability associated with dermal edema, e.g., induration, and especially the increased vascular permeability induced by vascular permeability factor
Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The invention relates to the use of biologically active glutarimide derivatives or pharmaceutically acceptable salts thereof as agents for the treatment of eosinophilic diseases.
BACKGROUND
Eosinophils are cells of the innate immunity. They are produced in the bone marrow and
Phospholipid analogs useful as PAF synthesis inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Platelet-activating factor (PAF) has been identified as an acetyl glyceryl ether phosphorylcholine (AGEPC), i.e., 1-O-hexadecyl/octadecyl-2-O-acetyl-sn-glycerol-3-phosphorylcholine [Hanahan, D. S. et al., J. Biol. Chem., 255:5514, (1980)]. Even before its chemical
Ionic aqueous polysaccharide compositions
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Sinonasal complaints affect at least 15% of the population in the United States of America with predictable patient morbidity and financial impact. Importantly, any modality that can alleviate sinonasal complaints warrants serious attention. Among various treatments
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This application is related to, not a continuing case to U.S. Pat. Nos. 6,172,060, 6,197,778, 6,177,428, 6,172,068, 6,221,881, 6,232,321, 6,197,782, 6,133,272, and 6,211,179.
FIELD OF THE INVENTION
The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions comprising at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, at least one compound that donates, transfers or
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions comprising at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, at least one compound that donates, transfers or
Substituted 2,3,3a,6-tetrahydro-6-oxobenzofuran derivative useful as PAF antagonist
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Platelet-activating factor (PAF) has recently been identified as an acetyl glyceryl ether phosphorylcholine (AGEPC), i.e., 1-O-hexadecyl/octadecyl-2-O-acetyl-sn-glycero-3-phosphorylcholine (Hanahan, D. S. et al., J. Biol. Chem., 255: 5514, 1980). It is a potent lipid
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
